Literature DB >> 20961185

Determination of daptomycin in human plasma by liquid chromatography-tandem mass spectrometry. Clinical application.

Marie-Clémence Verdier1, Danièle Bentué-Ferrer, Olivier Tribut, Nicolas Collet, Matthieu Revest, Eric Bellissant.   

Abstract

BACKGROUND: Daptomycin is a recently developed cyclic lipopeptide antibiotic active against most Gram-positive pathogens including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. To optimize treatment efficacy and safety, especially in patients undergoing multiple drug regimens and/or co-morbidities, a specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the quantification of daptomycin in plasma.
METHODS: A C18 column was used for separation, with a mobile phase initially consisting of 0.1% formic acid, water, and acetonitrile (ACN) in a linear gradient from 20% to 70%. After protein precipitation with ACN, the clear upper layer was diluted in water:ACN (50:50, v/v) before injection. Detection was performed using an electrospray ionization technique. MS/MS transitions, monitored in the positive ion mode were m/z 811.1 → m/z 313.1 for daptomycin, and m/z 609.4 → m/z 194.9 for reserpine, used as internal standard.
RESULTS: Elution of daptomycin and reserpine occurred at 4.5 and 3.9 min, respectively. The method was validated over a range of concentrations from 1 mg/L to 120 mg/L. The assay met recommended acceptance criteria: coefficients of variation were <6.3% and <7.4%, and accuracies were between -5.9% and +11.2% and between -3.5% and +3.7%, for intra- and inter-day validations, respectively.
CONCLUSIONS: This method appears well-adapted to routine hospital practice for therapeutic drug monitoring of daptomycin considering its time of analysis, range of concentrations measured, precision and accuracy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961185     DOI: 10.1515/CCLM.2011.005

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Pharmacokinetics of daptomycin in a patient with severe renal failure not receiving dialysis.

Authors:  Sandrine Marchand; Maider Lauda; Gwenael Le Moal; Patrice Gobin; William Couet; France Roblot
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

2.  Penetration of daptomycin into bone and synovial fluid in joint replacement.

Authors:  D Montange; F Berthier; G Leclerc; A Serre; L Jeunet; M Berard; P Muret; L Vettoretti; J Leroy; B Hoen; C Chirouze
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 3.  Clinical Pharmacokinetics of Daptomycin.

Authors:  Nicolas Gregoire; Alexia Chauzy; Julien Buyck; Blandine Rammaert; William Couet; Sandrine Marchand
Journal:  Clin Pharmacokinet       Date:  2020-12-14       Impact factor: 6.447

4.  Rapid Turbidimetric Assay to Determine the Potency of Daptomycin in Lyophilized Powder.

Authors:  Eliane Gandolpho Tótoli; Hérida Regina Nunes Salgado
Journal:  Pharmaceutics       Date:  2015-07-09       Impact factor: 6.321

5.  Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study.

Authors:  Makoto Saito; Shuji Hatakeyama; Hideki Hashimoto; Takumitsu Suzuki; Daisuke Jubishi; Makoto Kaneko; Yukio Kume; Takehito Yamamoto; Hiroshi Suzuki; Hiroshi Yotsuyanagi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-04-11       Impact factor: 3.944

6.  Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy.

Authors:  Chong Li; Xiaolin Zhang; Xinliang Huang; Xiaoying Wang; Guojian Liao; Zhangbao Chen
Journal:  Int J Nanomedicine       Date:  2013-03-24

Review 7.  Impact on Antibiotic Resistance, Therapeutic Success, and Control of Side Effects in Therapeutic Drug Monitoring (TDM) of Daptomycin: A Scoping Review.

Authors:  Carolina Osorio; Laura Garzón; Diego Jaimes; Edwin Silva; Rosa-Helena Bustos
Journal:  Antibiotics (Basel)       Date:  2021-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.